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Background: Burkholderia cepacia complex (BCC) bacteria are highly virulent, typically multidrug-resistant,
opportunistic pathogens in cystic fibrosis (CF) patients and other immunocompromised individuals. B. vietnamiensis
is more often susceptible to aminoglycosides than other BCC species, and strains acquire aminoglycoside resistance
during chronic CF infection and under tobramycin and azithromycin exposure in vitro, apparently from gain of
antimicrobial efflux as determined through pump inhibition. The aims of the present study were to determine if
oxidative stress could also induce aminoglycoside resistance and provide further observations in support of a role
for antimicrobial efflux in aminoglycoside resistance in B. vietnamiensis.
Findings: Here we identified hydrogen peroxide as an additional aminoglycoside resistance inducing agent in
B. vietnamiensis. After antibiotic and hydrogen peroxide exposure, isolates accumulated significantly less [3H]
gentamicin than the susceptible isolate from which they were derived. Strains that acquired aminoglycoside
resistance during infection and after exposure to tobramycin or azithromycin overexpressed a putative resistance-
nodulation-division (RND) transporter gene, amrB. Missense mutations in the repressor of amrB, amrR, were identified
in isolates that acquired resistance during infection, and not in those generated in vitro.
Conclusions: These data identify oxidative stress as an inducer of aminoglycoside resistance in B. vietnamiensis and
further suggest that active efflux via a RND efflux system impairs aminoglycoside accumulation in clinical B. vietnamiensis
strains that have acquired aminoglycoside resistance, and in those exposed to tobramycin and azithromycin, but not
hydrogen peroxide, in vitro. Furthermore, the repressor AmrR is likely just one regulator of the putative AmrAB-OprM efflux
system in B. vietnamiensis.
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Members of the Burkholderia cepacia complex (BCC)
can cause severe respiratory infections in individuals
with cystic fibrosis (CF) [1]. Furthermore, many strains
are highly and intrinsically resistant to various antimicro-
bials, including aminoglycosides [2], ribosome-targeting
antibiotics important in the treatment of CF respiratory
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stated.B. cenocepacia studies suggest that resistance-nodulation-
division (RND) efflux systems are involved in BCC resist-
ance to aminoglycosides [4-6]. The MexXY-OprM RND
pump is the predominant determinant of aminoglycoside
resistance in CF isolates of Pseudomonas aeruginosa [7],
and aminoglycoside susceptibility in B. pseudomallei
results from loss of AmrAB-OprA [8]. At subinhibitory
concentrations, ribosome-targeting antibiotics and oxida-
tive stress induce mexXY expression [9,10]. mexXY is
under the control of the MexZ repressor [11], and mexZ
mutations are common in pan-aminoglycoside resistant
isolates [12].
We previously reported that B. vietnamiensis isolates are
often aminoglycoside-susceptible and strains acquire resist-
ance during chronic CF infection and under tobramycinLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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of aminoglycosides to their target resulted from apparent
gain of antimicrobial efflux via a RND pump, the latter de-
termined with an inhibitor [13].
B. vietnamiensis develops aminoglycoside resistance
under hydrogen peroxide pressure in vitro
Aminoglycoside resistance can be induced in susceptible
CF isolates of B. vietnamiensis following serial exposure
to tobramycin (Table 1: C8395TE, D0072TE) or a single
exposure to subinhibitory concentrations of azithromycin
[13]. To characterize resistance inducing antimicrobial
pressures further, after serial passage in cation-adjusted
Mueller-Hinton broth (CAMHB) containing azithromy-
cin, meropenem, ceftazidime, and co-trimoxazole at doub-
ling concentrations as described previously [13] the drug
susceptibility of C8395 was evaluated. Triplicate minimum
inhibitory concentrations (MICs) were determined using
broth microdilution methods [14], and their stability
confirmed after 20 passages on antibiotic-free media.
P. aeruginosa and non-Enterobacteriaceae breakpoints
were used in the absence of B. cepacia breakpoints.
Only serial exposure of C8395 to azithromycin resulted
in notable (≥4 fold) increases in aminoglycoside MICs
(Table 1). By previously described methods [9], but with
selective agar containing tobramycin at 2.5 times the
MIC, serial exposure of C8395 to hydrogen peroxide
at half the MIC resulted in a 16-fold stable increase
in aminoglycoside MIC for C8395PE (Table 1). Other
acquired resistance was also observed: after passageTable 1 Antimicrobial susceptibilities of B. vietnamiensis after
Isolatea
AMK GEN KAN TO
Clinical CF
C8395 (3/11/1998, Bv1) 2 4 2 2
D0774 (25/7/2003, Bv1) >128 128 128 12
D0072 (15/03/2002, Bv3) 2 4 1 2
D2910 (31/03/2008, Bv3) 128 32 64 3
In vitro exposed
C8395TE (TOB) >128 >128 128 >1
C8395AE (AZM) 32 16 16 1
C8395ME (MEM) 16 8 8 8
C8395CE (CAZ) 8 8 4 4
C8395SE (SXT) 8 8 2 2
C8395PE (peroxide) 32 64 32 3
C8395PC (control) 8 8 4 8
D0072TE (TOB) 32 32 16 1
aPatient identification numbers and bacterial isolation dates are noted in brackets.
exposed; SE, SXT exposed; PE, hydrogen peroxide exposed; PC, passage control.
bAminoglycoside and azithromycin MICs for C8395 and D0774, and tobramycin and
published to some extent [13] and are shown here for comparison. MICs represent
amikacin; GEN, gentamicin; KAN, kanamycin; TOB, tobramycin; AZM, azithromycin; Mwith all antimicrobials the MICs of the respective
agents against C8395 increased greatly (Table 1:
C8395AE, C8395ME, C8395CE, and C8395SE), and
some other cross-resistance, most notably between
the β-lactams antibiotics, was also seen.
Hydrogen peroxide is, therefore, an additional inducer
of aminoglycoside resistance in B. vietnamiensis in vitro, a
particularly important finding because CF airways are rich
in reactive oxygen species [15]. Moreover, B. vietnamiensis
can acquire resistance after exposure to other antimicro-
bials used in treating BCC-infected CF patients, namely
meropenem, ceftazidime, and co-trimoxazole [16].
The aminoglycoside-resistant derived isolates C8395TE
and C8395PE accumulated 2.65 and 3.50 times less [3H]
gentamicin than C8395, respectively (P = 0.0118, one-way
ANOVA) (data not shown). Accumulation was deter-
mined in triplicate in Luria-Bertani (LB) medium as previ-
ously used to show the late, aminoglycoside-resistant
isolate D0774 accumulates less gentamicin than C8395
[13]. There were no significant differences in the
CFU/ml between C8395 and the comparison isolates
at starting time (data not shown). Decreased access of
aminoglycosides to their intracellular target is, therefore,
responsible for the observed in vitro antibiotic and
oxidative stress-induced resistance.
Analysis of putative efflux system genes in clinical and
in vitro stress exposed B. vietnamiensis isolates
Of the 11 putative RND transporters that the sequenced
environmental B. vietnamiensis isolate G4 (accessionserial exposure to antibiotics or hydrogen peroxide
MIC (μg/ml)b
B AZM MEM CAZ SXT CIP
32 1 4 2/10 1
8 >2048 128 128 64/320 >32
32 0.5 2 2/10 1
2 >32 2 4 1/5 16
28 64 1 4 4/20 4
6 2048 2 16 8/40 4
32 16 64 4/20 16
32 8 16 2/10 16
32 0.5 4 >64/320 8
2 32 4 16 4/20 4
32 1 4 1/5 1
6 >32 1 2 2/10 1
Abbreviations: TE, TOB exposed; AE, AZM exposed; ME, MEM exposed; CE, CAZ
azithromycin MICs for D0072, D2910, C8395TE, and D0072TE were previously
susceptibility after 3 passages on antibiotic-free media. Abbreviations: AMK,
EM, meropenem; CAZ, ceftazidime; SXT, co-trimoxazole; CIP, ciprofloxacin.
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following sequence alignment only Bcep1808_1575
showed high identity, 71%, 85%, and 92%, with the char-
acterized transporters MexY (accession NC_008463.1)
and AmrB (accession NC_007434.1), and their homologue
BCAL1675 in B. cenocepacia (accession NC_011000.1),
respectively. These transporters are part of an operon also
encoding a repressor, membrane fusion protein, and outer
membrane channel [7]. PCR product analysis revealed
that B. vietnamiensis clinical isolates C8395, D0774,
D0072, and D2910 contained these efflux system genes in
the same order (data not shown).
To evaluate the expression of RND pump genes in B.
vietnamiensis, triplicate overnight cultures were diluted
1:100 into CAMHB, LB medium, or synthetic cystic
fibrosis sputum medium (SCFM) [18] with or without
tobramycin and ceftazidime at half MIC or azithromycin,
meropenem, and co-trimoxazole at a quarter MIC, and
grown to an optical density at 600 nm (OD600) of 0.5 or
0.8. RNA was extracted using an RNeasy Plus Mini kit
(Qiagen, Toronto, Canada), and treated with RNase-free
DNase (Promega, San Luis Obispo, USA). Reverse tran-
scription was performed using SuperScript II Reverse
Transcriptase (Invitrogen, Carlsbad, USA) according to
the manufacturer’s protocol. Amplification of the resultant
DNA was quantified in a 7300 Real-Time PCR System
(Applied Biosystems, Carlsbad, USA) in the presence of
SybrGreen (Invitrogen), with primers for Bcep1808_1575
(5’-CCGAACGACATCTACTTCAAGGTCGG-3’, 5’-ATC
CTTCGCGACTTCGACGATCAG-3’), Bcep1808_1573 (pu-
tative repressor gene) (5’-TGCAGATCCTGCGGATCAC-
GAAA-3’, 5’-TTCGAGCAACGACACCAGATAGACG-3’),
and 16S (for normalization) (5’-CACGCTTTACGCCCAG
TAATTCCG-3’, 5’-CCGGAAGAATAAGCACCGGCTAAC-
3’). Denaturation occurred at 95°C for 10 minutes,
followed by 40–50 cycles of 15 seconds at 95°C and 1
minute at 60°C.
The late, aminoglycoside-resistant isolate D0774
expressed 11.4-, 9.6-, and 8.0-fold more Bcep1808_1575,
herein “amrB”, than the early, aminoglycoside-susceptible
isolate C8395, at OD600 of 0.8 in CAMHB, LB medium,
and SCFM, respectively (P < 0.01) (Figure 1A). amrB
expression between D0774 and C8395 was, however, 2.7
times less at OD600 of 0.5 vs 0.8 (P < 0.001) (Figure 1A),
owing to D0774 expressing less amrB earlier (P < 0.01)
(data not shown). Compared with C8395, D0774 also
expressed 3.6- and 3.2-fold more Bcep1808_1573,
herein “amrR”, at OD600 of 0.8 in CAMHB and SCFM,
respectively (P < 0.01) (Figure 1A). In another set of se-
quential isolates, the late, aminoglycoside-resistant isolate
D2910 also overexpressed amrB (by 5.3-fold) and amrR
(by 2.4-fold) compared with the early, aminoglycoside-
susceptible D0072 at OD600 of 0.8 in CAMHB (data not
shown).After a single exposure of C8395 to subinhibitory
concentrations of test antimicrobials in CAMHB, amrB
expression did not change (data not shown). After expos-
ure of C8395 to serially doubling concentrations of tobra-
mycin or azithromycin but not to other antibiotics or
hydrogen peroxide (i.e. in C8395TE and C8395AE),
expression of amrB increased 9.9- and 8.6-fold, respect-
ively (P < 0.01) (Figure 1B, data not shown). Compared
with C8395, C8395TE also expressed 14.2-fold less
amrR (P < 0.01) (Figure 1B).
Active efflux via a RND efflux system is, therefore,
probably involved in the decreased drug accumulation
observed in B. vietnamiensis strains that acquired ami-
noglycoside resistance during infection and after expos-
ure to tobramycin and azithromycin in vitro, owing to
the correlation between resistance and amrB expression.
Other aminoglycoside resistance determinants exist,
since exposure to hydrogen peroxide did not induce
amrB expression, and future tests with minimal medium
would demonstrate that absoluteness of these observa-
tions. As proposed previously [19], amrB upregulation
only in response to ribosome-targeting agents suggests it
is a response to this interaction, not to antibiotics per se.
Moreover, amrB overexpression was not sufficient to
cause resistance to non-aminoglycoside antibiotics,
supporting the notion that they are not substrates for
the putative AmrAB-OprA efflux system [13]. Lastly,
there was no association between amrR expression
and aminoglycoside resistance or amrB expression, as
is also true for mexZ [20].
To determine if mutations in amrR were responsible for
the observed overexpression of amrB in B. vietnamiensis,
sequences of the putative repressor were examined. DNA
isolation, PCR using Phusion High-Fidelity DNA Poly-
merase (New England Biolabs, Ipswich, USA) with
specific primers (5’-TTCAAAGAGGTGTGGGCAGGA-3’,
5’-CCGAAACCCGTGTTGTTCATC-3’), and product ana-
lysis by agarose gel electrophoresis were done using stand-
ard protocols [21]. PCR products were purified with a
Wizard SV Gel and PCR Clean-Up System (Promega) and
cloned into One Shot TOP10 E. coli cells with a Zero Blunt
TOPO PCR Cloning Kit (Invitrogen). Plasmid DNA was
isolated using a QIAprep Miniprep Kit (Qiagen), and
M13 primers amplified amrR. Resultant products were
sequenced at the UBC Centre for Molecular Medicine
and Therapeutics.
C8395 and D0774 amrR differed from that of G4
by two silent mutations (data not shown). The late,
aminoglycoside-resistant isolate D0774 also contained a
substitution at position 425 (T→ C), that at residue 142
of the protein, in the suggested ligand binding alpha
helix region [22], replaces a leucine with a proline. D0072
and D2910 amrR sequences also differed: at position 156,
or amino acid residue 52 amid the predicted DNA and
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~2000 bp insertion in the late, aminoglycoside-resistant
D2910. Only silent mutations were observed in amrR
among C8395, C8395TE, C8395AE, C8395PE, and
C8395PC (data not shown).
The amrR mutations identified likely influenced the
expression of the putative B. vietnamiensis amrB trans-
porter gene. The change in D0774 AmrR may indirectly
affect DNA binding to the transcription factor [22], whileFigure 1 Expression of the putative RND efflux system genes amrB an
exposed B. vietnamiensis isolates. Expression was determined by real-tim
aminoglycoside-susceptible isolate C8395, and the late, aminoglycoside-res
between C8395 before and after its exposure to various antimicrobials, peroxi
were taken for each biological replicate. Fold change means were calculated
of (A) D0774 or (B) condition. Data points represent the averages of three biolo
Student’s t-test. (B) *, P< 0.05; **, P< 0.01 by Dunnett’s Multiple Comparison Tes
Bcep1808_1573; RND, resistance-nodulation-division; CAMHB, cation-adjusted Mu
sputum medium; OD600, optical density at 600 nm.the large insertion within D2910 amrR likely inactivates
the repressor altogether. As per the in vitro derived isolate
findings, aminoglycoside-resistant P. aeruginosa isolates
overexpressing mexXY without mutations in mexZ also
exist [23,24].
In conclusion, in B. vietnamiensis, oxidative stress
can induce aminoglycoside resistance, while active efflux
via the putative AmrAB-OprM efflux system is likely
involved in clinical and in vitro antimicrobial-inducedd amrR in clinical CF and in vitro antibiotic or hydrogen peroxide
e reverse transcription PCR and compared (A) between the early,
istant D0774, in various types of media and stages of growth, and (B)
de, or passage alone in CAMHB. The averages of three technical repeats
by comparing the mean expression in C8395 to each biological replicate
gical replicates ± standard errors. (A) **, P< 0.01; *** P< 0.001 by unpaired
t after one-way ANOVA. Abbreviations: amrB, Bcep1808_1575; amrR,
eller-Hinton broth; LB, Luria-Bertani medium; SCFM, synthetic cystic fibrosis
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inducing conditions and resistance factors may improve
therapeutic regimens against infection with this species.
Additional mechanisms of aminoglycoside resistance
should be investigated next. The contribution of resistance
determinants to aminoglycoside inefficacy may explain the
observed varied degrees of resistance.
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